HIV prevention drug : billions in corporate profits after millions in taxpayer investments : hearing before the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, first session, May 16, 2019.

Format:

Book

Government document

Author/Creator:

United States. Congress. House. Committee on Oversight and Reform, author.

Language:

English

Subjects (All):

Gilead Sciences (Firm).

Pre-exposure prophylaxis--Prices--United States.

Pre-exposure prophylaxis.

Pre-exposure prophylaxis--United States--Cost control.

HIV infections--United States--Prevention.

HIV infections.

Emtricitabine/tenofovir disoproxil fumarate--United States.

Emtricitabine/tenofovir disoproxil fumarate.

Prescription pricing--Government policy--United States.

Prescription pricing.

Pharmaceutical industry--Prices--Government policy--United States.

Pharmaceutical industry.

Medical policy--United States.

Medical policy.

Federal aid to medical research--United States.

Federal aid to medical research.

HIV infections--Prevention.

Prescription pricing--Government policy.

United States.

PrEP.

HIV/AIDS.

Genre:

Legislative hearings

Legislative hearings.

Physical Description:

1 online resource (iii, 63 pages)

Other Title:

Human Immunodeficiency Virus prevention drug

Billions in corporate profits after millions in taxpayer investments

Place of Publication:

Washington : U.S. Government Publishing Office, 2019.

Notes:

"Serial no. 116-24."

Description based on online resource; title from PDF title page (govinfo, viewed Aug. 12, 2019).

Other Format:

Print version: United States. Congress. House. Committee on Oversight and Reform. HIV prevention drug

Microfiche version: United States. Congress. House. Committee on Oversight and Reform. HIV prevention drug

OCLC:

1112074275